Review of light therapy studies confirms its potential for helping Alzheimer’s patients
By
Aaron Dorman
Dec 08, 2023
A review of recent literature on light therapy reiterated that it improved sleep and behavior issues for those living with Alzheimer’s disease.
App that completes sentences for dementia patients a big winner
By
Aaron Dorman
Jun 21, 2023
An Amicus Brain Innovations virtual speech assistant will utilize artificial intelligence to echo a “modified,” more cohesive version of a users’ impaired speech.
Sensitivity study shines a light on how Alzheimer’s patients could benefit from carefully managed sleep...
By
Aaron Dorman
Aug 01, 2023
Light therapy could be a vital tool for people living with Alzheimer’s to manage or slow the disease, a new study shows.
Straight from the gut: AI helps researchers confirm Alzheimer’s link
By
John O'Connor
Apr 24, 2024
Cleveland Clinic researchers are using artificial intelligence to confirm the link between the gut microbiome and Alzheimer’s disease.
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
More frequent hearing aid use could help stave off dementia, experts suggest
By
Aaron Dorman
Jan 08, 2024
Newly available non-prescription hearing aid use could have major overall health benefits and reduce the risk of dementia, experts say.
Brain imaging company teases tech that will analyze side effects of new dementia drugs
By
Aaron Dorman
Nov 28, 2023
AI-enabled brain imaging technology will be launched next year to evaluate the side effects of new Alzheimer’s and dementia drugs.
Visionary Alzheimer’s forecasting software gets FDA approval
By
Aaron Dorman
Jan 30, 2024
A newly regulated Alzheimer’s software tool offers clarity on whether the condition is likely to progress to dementia in someone with mild cognitive impairment.
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
AI-driven speech analysis firm working to diagnose Alzehimer’s, Huntington’s
By
Aaron Dorman
Jun 27, 2023
A speech analysis software company is using Voice AI to diagnose depression and anxiety, and diseases like Alzheimer’s and Huntington’s could be next.